Germany – Pharmaceutical products – Abschluss von nicht-exklusiven Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Ranolazin

GWQ ServicePlus AG intends to conclude non-exclusive discount agreements pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V), for the aforementioned active ingredient, with a contract start date of February 1, 2023. All interested companies can join this agreement at any time during its term under the same conditions (approval model). GWQ assumes that this procedure, due to the absence of a selection process and thus the non-discriminatory access for all pharmaceutical companies, does not fall within the scope of public procurement law. The contract documents, the participating health insurance funds and their sales figures, as well as the deadlines for reporting the contract, can be viewed and downloaded from the GWQ ServicePlus AG procurement portal at http://vergabeportal.gwq-serviceplus.de. Until the start of exclusive contracts, this transitional agreement is open to all market participants. Upon receipt of the signed contracts/declaration and supporting documents by January 10, 2023, initial notification can be submitted on February 1, 2023. The following documents must be submitted: — signed contract in duplicate, — proof of marketing authorization by means of an extract from the public section of the AMIce database, — signed self-declaration (Annex 3), — list of the PZNs covered by the contract (Annex 2), — declaration regarding Council Regulation (EU) 2022/576 of April 8, 2022, amending Regulation (EU) No 833/2014 on restrictive measures in view of the actions of Russia which are destabilizing the situation in Ukraine (Annex 5)